---
schema_version: "secwatch.filing_event.v1"
accession: "0000875320-25-000171"
form_type: "8-K"
ticker: "VRTX"
cik: "0000875320"
company_name: "VERTEX PHARMACEUTICALS INC / MA"
filed_at: "2025-05-05T23:59:59+00:00"
generated_at: "2026-05-22T21:39:01.000388+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vertex Q1 revenue $2.77B (+3% YoY); GAAP net income falls to $646M on $379M impairment; FY guidance raised

## Summary
- Revenue $2.77B, +3% YoY; US revenue +9% to $1.66B, ex-US -5% to $1.11B due to Russia IP violation.
- GAAP net income $646M vs $1.1B Q1 2024; includes $379M impairment charge on discontinued VX-264 T1D program.
- Non-GAAP net income $1.1B vs $1.2B; combined non-GAAP R&D, AIPR&D and SG&A expenses $1.2B.
- Raised FY2025 revenue guidance low end to $11.85B-$12B (from $11.75B-$12B); reiterates expense guidance.
- JOURNAVX launch: >20,000 prescriptions filled since March; ~94M lives have covered access.

## SEC filing metadata
- accession: 0000875320-25-000171
- form_type: 8-K
- ticker: VRTX
- cik: 0000875320
- company_name: VERTEX PHARMACEUTICALS INC / MA
- filed_at: 2025-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875320/000087532025000171/0000875320-25-000171-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875320/000087532025000171/vrtx-20250505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875320-25-000171
- JSON: https://secwatch.observer/filing/0000875320-25-000171.json
- Plain text: https://secwatch.observer/filing/0000875320-25-000171.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.